» Articles » PMID: 33150314

Clinical Features and Predictors of Remission in Children Under the Age of 7 Years with Graves' Disease

Overview
Specialty Pediatrics
Date 2020 Nov 5
PMID 33150314
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: Graves' disease (GD) is rare in children under the age of 7 years. Children with this disease exhibit greater thyrotoxicity at diagnosis and require a longer course of medical therapy, compared with pubertal and postpubertal children and adults.

Objective: To investigate the clinical features and identify predictors of remission in children under the age of 7 years with GD.

Methods: This retrospective study included 77 children who were diagnosed with GD under the age of 7 years and were treated in the Department of Endocrinology, Beijing Children's Hospital from 2010 to 2018. Clinical manifestations, laboratory data, and follow-up records were collected for all patients. Children who achieved remission of treatment with methimazole were compared with those who had persistent disease to identify which variables were associated with remission; multiple logistic regression and Cox regression analyses were used to evaluate interactions among predictive variables.

Results: Sixty-three boys and 14 girls were included; the median age at diagnosis was 4.2 years (interquartile range: 3.2-5.3 years). Forty-six (56.7%) patients had no family history of thyroid disease, 17 patients had family history of thyroid disease and 14 patients with unknown family history. Of the 77 patients, 18 (23.4%) patients achieved remission of treatment with methimazole and 59 patients did not; moreover, 51 (66.2%) had Graves' ophthalmopathy. Univariate analyses revealed no significant differences between the remission group and non-remission group in terms of age at diagnosis, sex, initial goiter size, or initial thyroid hormone concentration. However, there were a trend of correlation between the initial level of thyroid peroxidase antibody (TPOAb) and remission status (univariate analysis 1.002, 0.038; multivariate analysis 1.004, 0.019). Similar results were observed in univariate analysis of the initial thyrotropin receptor antibody (TRAb) level, but this association was not significant in multivariate analysis. Cox regression analyses revealed that children with high TRAb level required longer duration of remission, compared with low TRAb level ( 0.950, 95% 0.904-0.997, 0.037).

Interpretation: Initial TRAb level was an independent predictor of remission outcome in young children under the age of 7 years with GD. Initial TRAb level may predict the likelihood of remission in patients with young-age-of-onset GD.

Citing Articles

Effect of Antithyroid Drugs Treatment Duration on The Remission Rates of Graves' Disease in Children and Adolescents: A Single-Arm Meta-Analysis and Systematic Review.

Li Y, Wang X, Shi W, Chen J, Song Y, Gong C Clin Endocrinol (Oxf). 2024; 102(2):196-204.

PMID: 39501471 PMC: 11694547. DOI: 10.1111/cen.15159.


Longitudinal follow-up of pediatric Graves' disease in preschool children: Clinical characteristics and a case report.

Yang J, Kao L, Chuang L, Chen H Medicine (Baltimore). 2023; 102(19):e33680.

PMID: 37171351 PMC: 10174402. DOI: 10.1097/MD.0000000000033680.


Graves' Disease in Children: An Update.

Metwalley K, Farghaly H Clin Med Insights Endocrinol Diabetes. 2023; 16:11795514221150615.

PMID: 37151843 PMC: 10161304. DOI: 10.1177/11795514221150615.


Remission in pediatric Graves' disease treated with antithyroid drug and the risk factors associated with relapse.

Wong T, Wong M Ann Pediatr Endocrinol Metab. 2022; 27(4):308-314.

PMID: 36567464 PMC: 9816462. DOI: 10.6065/apem.2244038.019.


Clinical features and predictors of remission in children under the age of 7 years with Graves' disease.

Gu Y, Liang X, Liu M, Wu D, Li W, Cao B Pediatr Investig. 2020; 4(3):198-203.

PMID: 33150314 PMC: 7520111. DOI: 10.1002/ped4.12219.

References
1.
Shulman D, Muhar I, Jorgensen E, Diamond F, Bercu B, Root A . Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid. 1998; 7(5):755-60. DOI: 10.1089/thy.1997.7.755. View

2.
Kaguelidou F, Alberti C, Castanet M, Guitteny M, Czernichow P, Leger J . Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab. 2008; 93(10):3817-26. DOI: 10.1210/jc.2008-0842. View

3.
Bahn Chair R, Burch H, Cooper D, Garber J, Greenlee M, Klein I . Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011; 21(6):593-646. DOI: 10.1089/thy.2010.0417. View

4.
Mayer-Davis E, Lawrence J, Dabelea D, Divers J, Isom S, Dolan L . Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012. N Engl J Med. 2017; 376(15):1419-1429. PMC: 5592722. DOI: 10.1056/NEJMoa1610187. View

5.
Rivkees S, Stephenson K, Dinauer C . Adverse events associated with methimazole therapy of graves' disease in children. Int J Pediatr Endocrinol. 2010; 2010:176970. PMC: 2833412. DOI: 10.1155/2010/176970. View